HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place...
Hence then, the article about ivonescimab first line biliary tract cancer phase iii overall survival data selected as esmo late breaking abstract nearly 30 akeso studies to be presented at esmo 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026 )
Also on site :
- Adam Sandler and His Wife Go Incognito in NYC; 60-Year-Old Comedian Is Nearly Unrecognizable Rocking a Bright Purple Hoodie
- Brooklyn Beckham Shares Tribute to Presley Gerber: ‘You Were the Kindest’
- Shakira Kicks Off Madrid Residency With 165,000-Fan Opening Weekend, Laura Pausini, and Setlist Surprises